Welcome to Markets Desk, here's what's moving the needle this afternoon.
Equities ended Monday in mixed territory, with the S&P five hundred barely slipping by less than a tenth of a percent while the Dow eked out a gain of roughly a third of a point. The Nasdaq bore the most pressure, down nearly half a percent, as geopolitical uncertainty around Iran kept risk appetite cautious and traders reluctant to extend positions heading into the week.
Shifting to pharma, Neurocrine Biosciences used the American Psychiatric Association's two thousand twenty six annual meeting to present fresh survey data on INGREZZA in patients with mild tardive dyskinesia. The company simultaneously closed its Soleno acquisition, a deal that broadens its rare disease portfolio and signals management is pushing growth on two fronts simultaneously — pipeline depth and commercial expansion.
And in a story that sits at the intersection of luxury and mass market strategy, Audemars Piguet's collaboration with Swatch triggered scenes of genuine chaos at retail locations globally — long queues, fistfights, and in at least one location, tear gas. The four hundred dollar watches sold out instantly, raising serious questions about whether the prestige brand is harvesting short-term hype at the cost of the exclusivity that defines its identity at the top of the market.
That's the tape. Markets Desk, signing off the floor.